The hepatitis C drugs, which cured a vast majority of patients in clinical trials, are essentially a one-time cost. The cholesterol drugs, by contrast, will be taken for a lifetime. At these rates, the lifetime costs could be staggering. Read More
Two powerful new drugs that can sharply lower cholesterol are vastly overpriced based on the value they provide, according to a new analysis by an independent organization that evaluates pharmaceutical costs. Read More
The pharmaceutical industry have, in recent years, focused on development of so-called specialty drugs and have priced them aggressively. These prices, such as the US$1,000 per pill price for the hepatitis C drug sofosbuvir, are alarming for patients, employers, insurers, and governments. Read More
“With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market,” John Rother, leader of the Campaign for Sustainable Rx Pricing, said in a statement. Read More
"The approval of Repatha is another example of a breakthrough medication with a too high price tag. With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market.” Read More
Our effort—the Campaign for Sustainable Rx Prices—has been sounding the alarm for more than a year that pharmaceutical companies must come to the table with meaningful solutions to the challenge of rising drug costs. Otherwise, companies risk the rising tide of consumer anger resulting in solutions that are not constructive for anyone. Read More
PRESS STATEMENT For Immediate Release August 20, 2015 Contact: John Rother… Read More
This is an important time to think about the future of programs and policies that support us as we age. Medicare marks its 50th Anniversary at the end of July. I’ve been around to witness much of the creation and evolution of health policy. After a 40-year career in Aging and Health Policy, first in the Senate, then at AARP, and now as head of the National Coalition on Health Care, I have a few observations about where things stand. Read More
“These numbers paint a troubling picture for the future of the American economy. The dramatic rise in prescription drug spending proves that it is more important than ever to advance a solution to monopolistic drug pricing. We cannot afford to continue on this unsustainable path.” Read More
“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but its price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years," John Rother, president of the National Coalition on Health Care, said in a statement. Read More
“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.” Read More
In recent years, increasingly specialized medications and an aging population that takes more drugs have substantially boosted the price of treatments for cancer, hepatitis C, cystic fibrosis and other diseases. Read More